ISAC Regulatory Compliance 3 — Questions and Answers
Question 1: In a GMP-compliant cell therapy manufacturing facility using flow cytometry for release testing, which document type specifies the acceptable ranges for each release parameter?
- Standard Operating Procedure (SOP)
- Certificate of Analysis (CoA)
- Product Specification document (Correct answer)
- Deviation Report
Correct answer: Product Specification document
A Product Specification document defines the predetermined acceptance criteria that a cell therapy product must meet on release testing, including flow cytometric parameters.
Question 2: Which validation element distinguishes 'verification' from 'validation' when a clinical lab adopts an FDA-cleared flow cytometry assay?
- Verification confirms the lab can replicate manufacturer claims; validation establishes performance for a new intended use (Correct answer)
- Validation is required only for LDTs; verification is required for all tests
- Verification requires FDA submission; validation does not
- They are synonymous under CLIA regulations
Correct answer: Verification confirms the lab can replicate manufacturer claims; validation establishes performance for a new intended use
For FDA-cleared assays, CLIA requires verification (confirming manufacturer performance claims), while full validation is required when the intended use or conditions differ from the cleared indication.
Question 3: A laboratory notices a systematic shift in CD4 counts after replacing a laser module. According to good laboratory practice, the FIRST action should be:
- Report the shift to the FDA as a device malfunction
- Perform a full analytical verification before resuming patient testing (Correct answer)
- Adjust the normal reference ranges to match the new results
- Discard all results from the prior month
Correct answer: Perform a full analytical verification before resuming patient testing
Any hardware change affecting measurement quality requires a new verification of analytical performance before patient results can be reported.
Question 4: Under CAP Flow Cytometry Checklist requirements, how frequently must an operator perform and document instrument daily quality control before patient testing?
- Weekly, with monthly review by the laboratory director
- Each day of patient testing (Correct answer)
- Monthly, using a six-point calibration curve
- Annually, coinciding with proficiency testing cycles
Correct answer: Each day of patient testing
CAP requires that daily QC be performed and documented each day patient specimens are analyzed to ensure instrument performance is within acceptable limits.
Question 5: The EU In Vitro Diagnostic Regulation (IVDR 2017/746) replaced the IVDD and introduced stricter classification rules. Under IVDR, most flow cytometry reagents used for patient diagnosis would likely fall into which risk class?
- Class A (lowest risk, self-declaration)
- Class B (moderate risk)
- Class C (high risk, Notified Body review required) (Correct answer)
- Class D (highest risk, batch release required)
Correct answer: Class C (high risk, Notified Body review required)
Under IVDR, reagents used for serious or life-threatening disease diagnosis (e.g., oncology immunophenotyping) are typically Class C, requiring Notified Body conformity assessment.
Question 6: Which element is NOT typically required in a flow cytometry laboratory's Quality Management System (QMS) under ISO 15189?
- Document control procedures
- Personnel training and competency records
- Management review meetings
- Manufacturer profit margin disclosures (Correct answer)
Correct answer: Manufacturer profit margin disclosures
ISO 15189 requires document control, competency management, and management review, but financial disclosures from manufacturers are not part of a laboratory QMS.
Question 7: When shipping patient-derived specimens for flow cytometry analysis by a reference laboratory, which US regulation governs the packaging and labeling of the biohazardous material?
- DOT 49 CFR Part 173 — Shippers General Requirements for Shipments and Packagings (Correct answer)
- OSHA 29 CFR 1910.1030 — Bloodborne Pathogens Standard
- FDA 21 CFR Part 58 — Good Laboratory Practice
- EPA 40 CFR Part 261 — Hazardous Waste Identification
Correct answer: DOT 49 CFR Part 173 — Shippers General Requirements for Shipments and Packagings
The US Department of Transportation 49 CFR Part 173 regulates the packaging, labeling, and transport of biological substances, including patient specimens shipped as Category B infectious substances.
ISAC Regulatory Compliance 3
In a GMP-compliant cell therapy manufacturing facility using flow cytometry for release testing, which document type specifies the acceptable ranges for each release parameter?